These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 10197295

  • 21. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP, Wilson M, Jacob P, Benowitz NL.
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [Abstract] [Full Text] [Related]

  • 22. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B, Sáenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E.
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [Abstract] [Full Text] [Related]

  • 23. Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children.
    Mayayo-Sinués E, Fanlo A, Sinués B, Mayayo E, Labarta JI, García de Jalón A, Ferrández-Longás A.
    Eur J Clin Pharmacol; 2006 Feb; 62(2):123-7. PubMed ID: 16408225
    [Abstract] [Full Text] [Related]

  • 24. Acetylator phenotyping via analysis of four caffeine metabolites in human urine by micellar electrokinetic capillary chromatography with multiwavelength detection.
    Guo R, Thormann W.
    Electrophoresis; 1993 Feb; 14(5-6):547-53. PubMed ID: 8354241
    [Abstract] [Full Text] [Related]

  • 25. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
    Abraham K, Geusau A, Tosun Y, Helge H, Bauer S, Brockmöller J.
    Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
    [Abstract] [Full Text] [Related]

  • 26. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
    Nyéki A, Buclin T, Biollaz J, Decosterd LA.
    Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
    Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M.
    Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe].
    Li J, Peng XQ, Zhang J, Xu JP.
    Yao Xue Xue Bao; 2006 Mar; 41(3):282-4. PubMed ID: 16759004
    [Abstract] [Full Text] [Related]

  • 33. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN, Han Y, Tu JH, Zhou G, Huang YF, Zhou HH.
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
    [Abstract] [Full Text] [Related]

  • 34. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH, Nierenberg DW, Bresnick E.
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [Abstract] [Full Text] [Related]

  • 35. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers.
    Murayama N, Shimizu M, Kobayashi K, Kishimoto I, Yamazaki H.
    Drug Metab Lett; 2017 Mar; 10(4):240-243. PubMed ID: 27842485
    [Abstract] [Full Text] [Related]

  • 36. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
    Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sörgel F, Fuhr U.
    Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
    [Abstract] [Full Text] [Related]

  • 37. Dietary effects of Sideritis scardica "mountain tea" on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects.
    Begas E, Kilindris T, Kouvaras E, Tsioutsioumi A, Kouretas D, Asprodini EK.
    Food Chem Toxicol; 2018 Dec; 122():38-48. PubMed ID: 30266316
    [Abstract] [Full Text] [Related]

  • 38. Altered activity of xenobiotic detoxifying enzymes at menopause - A cross-sectional study.
    Tsiokou V, Kilindris T, Begas E, Kouvaras E, Kouretas D, Asprodini EK.
    Environ Res; 2020 Mar; 182():109074. PubMed ID: 31923849
    [Abstract] [Full Text] [Related]

  • 39. Pantoprazole lacks induction of CYP1A2 activity in man.
    Hartmann M, Zech K, Bliesath H, Steinijans VW, Koch H, Wurst W, Mascher H.
    Int J Clin Pharmacol Ther; 1999 Apr; 37(4):159-64. PubMed ID: 10235417
    [Abstract] [Full Text] [Related]

  • 40. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
    Tang BK, Zhou Y, Kadar D, Kalow W.
    Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.